Replies to post #334068 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Big hit with Rett. Homerun with PDD.

I am trying to understand which positive results, Rett or PDD OLE, has the most impact to AVXL stock price, sure both positive is the homerun outcome, thanks again.

That’s the question all of us long-term AVXL holders are asking. I’ve had most of my shares for a good number of years, awaiting for the market to buy in.

Both retail and institutional equity investors are waiting for data that will confidently foretell success for Anavex. Right now, not many can see that; everything too iffy. The company is targeting, of all things, three CNS diseases, for which no useful or good therapy really exists. The reluctance of most to take even a small AVXL position is both reasonable and understood. Nothing is going to change that until profoundly substantiating data appear; most favorably from any one of the ongoing clinical trials.

That may be the answer. The first trial to show that blarcamesine really does safety and significantly treat a CNS disease will substantiate the drug’s unique mechanisms of action (MOAs) in the CNS. If it can work in one, it will then appear reasonable that it will go on to work in one or two others.

So, I’m predicting that things will dramatically change with the Rett results. Perhaps not instantly, as the clinical results may be a bit hard to connect with. Rett is rare disease. But, then, mothers with Rett daughters being successfully treated with blarcamesine will be free to answer reporters’ questions. There will be increasing numbers of news articles telling about “a new drug showing promise for difficult CNS diseases.” The human factor will finally come into play.

Next, in time order, will be the Parkinson’s disease dementia study. When the public learns of people who regained cognitive skills, there will be no other questions. Anavex has it. If blarcamesine fixes cognitive deficits in Parkinson’s, it can be understood that it will also with Alzheimer’s; before that trial ends.

Next year, or maybe late this year, things are going to be very exciting. The Anavex medical revolution will begin. And we’ve been able to watch it almost from the beginning, before the general public ever heard of “blarcamesine” or “Anavex.”